CNTX logo

CNTXContext Therapeutics Inc

$1.42
$0.03
(2.07%)
Today
Closed $1.42
$0.02
(1.41%)
After Hours
Updated: 07:33 PM EDT
Mkt Cap$133.22M
Vol557,956.00
News
all
press releases
Context Therapeutics (NASDAQ:CNTX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS
Context Therapeutics (NASDAQ:CNTX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03...
MarketBeat
News Placeholder
More News
News Placeholder
Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday
Context Therapeutics (NASDAQ:CNTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...
MarketBeat
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Shares Down 7% - Time to Sell?
Context Therapeutics (NASDAQ:CNTX) Shares Down 7% - Here's What Happened...
MarketBeat
News Placeholder
Neogen Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary
Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive...
Business Wire
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded Context Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...
MarketBeat
News Placeholder
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine research firms that are currently covering the stock, MarketBeat...
MarketBeat
News Placeholder
Q1 EPS Forecast for Context Therapeutics Lowered by Analyst
Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities research analysts at Lifesci Capital reduced their Q1 2026 earnings per share estimates for Context Therapeutics in a report issued on...
MarketBeat
News Placeholder
HC Wainwright Brokers Reduce Earnings Estimates for CNTX
Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for Context Therapeutics in a research report...
MarketBeat
News Placeholder
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital restated a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Tuesday...
MarketBeat
News Placeholder
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim
Guggenheim restated a "buy" rating and issued a $5.00 target price on shares of Context Therapeutics in a research note on Tuesday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.